Many hidden genetic variations can be detected with Chameleolyser, a new method developed in Nijmegen. The information is already yielding new patient diagnoses and may also lead to the discovery of as yet unknown disease genes, write Wouter Steyaert and Christian Gilissen of Radboudumc in Nature Communications.
Medical science has been using exome sequencing to map the genes of individual patients with rare diseases for about 15 years. With this technique, the DNA of a person's approximately 20,000 human genes are cut into small pieces so the DNA letters can be read off. This creates a huge amount of tiny DNA fragments, which are then reassembled into whole genes like a jigsaw puzzle. The result is an overview of that single person's 20,000 genes.
Evolutionary engine
'Unfortunately, such an overview is never quite complete,' says Christian Gilissen, professor of Genome Bioinformatics. 'That’s because of the evolution of our genome, our hereditary material. When copying DNA, things sometimes go wrong. Small pieces of DNA disappear or are added. Some pieces are copied more than once. It also happens that a copied gene is placed somewhere else in the genome, giving you a pseudogene in addition to the original gene. These genetic "sloppinesses" are very important because they are the engine of evolution. This is how genetic changes arise. Changes that can be without effect or beneficial, but sometimes also cause new diseases.'
Confusing pseudogenes
Zooming in on the gene and pseudogenes for a moment. The gene has a function, the pseudogen usually does not. Over time, small changes, mutations, can occur in both the gene and pseudogen. But gene and pseudogen are so similar that when sequencing it is not clear which piece belongs to the gene and which to the pseudogen. Gilissen: ‘For this reason, these DNA regions are not included in the analysis. A mutation found may originate from the pseudogen and have no meaning. If you add that mutation to the normal gene, you would make a wrong diagnosis. We don't want that.’
Making the invisible visible
With Wouter Steyaert, Gilissen developed a method - Chameleolyser - that detects gene and pseudogen combinations in existing exome sequencing data and can also visualize the genetic variations between them. Steyaert: ‘We are now picking up a lot of genetic variation that was previously invisible. Per exome, we find about sixty additional genetic variants. For a number of people, this data allowed us to definitively determine the cause of their disease. With a new sequencing technique from PacBio, which analyzes longer stretches of DNA, we have established the reliability of our method.'
New disease genes, new diagnoses
The new method is interesting because it can be applied to already existing exome sequencing data. Thus, no new studies in patients are necessary. Any sequencing center in the world can apply the method. 'Such a large-scale analysis can also provide new biological insights,' Gilissen says. 'In many disorders, the genetic cause can only be determined in half of the patients. We think we will also find new disease genes in those gene-pseudogen combinations. For some of those patients, that may be where the genetic cause for their condition lies.'
-
Paper in Nature Communications: Systematic analysis of paralogous regions in 41,755 exomes reveals clinically relevant variation - Wouter Steyaert, Lonneke Haer-Wigman, Rolph Pfundt, Debby Hellebrekers, Marloes Steehouwer, Juliet Hampstead, Elke de Boer, Alexander Stegmann, Helger Yntema, Erik-Jan Kamsteeg, Han Brunner, Alexander Hoischen & Christian Gilissen
https://www.nature.com/articles/s41467-023-42531-9
-
Want to know more about these subjects? Click on the buttons below for more news.
More information
Pieter Lomans
persvoorlichter
Related news items
Women more likely to develop mild variant Stargardt's disease
24 May 2024In the mild form of Stargardt's disease, an inherited eye disease, women are more likely to experience vision problems than men. This is shown in doctoral research by Stéphanie Cornelis.
read moreRadboudumc participates in HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders Aim to Share Best Practices and Increase the Understanding of Genetic Disease
22 November 2023HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders including Radboudumc, is going to start
read moreAdvancing Therapies for Pediatric Renal Ciliopathies - TheRaCil
5 October 2023The Imagine Institute will coordinate the project Therapies for Renal Ciliopathies (TheRaCil), a project funded through Horizon Europe for the period 2021-2027 in which Radboudumc participates.
read more